TL;DR

I bought 1,000 shares of HIMS at $33.03 the night an FDA advisory panel started voting yes on the peptides story. By the next morning I was down 11%. The panel said yes; the stock said you’re late.

  • The catalyst had a public date since April. The stock ran roughly +58% in the three months before the meeting — that run was the market pre-paying for the yes.
  • On vote day the panel backed peptide after peptide — and HIMS still fell, because an advisory yes was the most expected outcome in the room, and it isn’t even the final decision.
  • My own scanner graded HIMS AVOID the night I bought it. I overrode the tools for a story.
  • The fix: an agent now scans regulatory calendars for future decision points, so the next runway gets caught in month one, not hour eleven. Briefs publish on the trading page.

I’m writing these down so I can check later whether my reasoning was any good. Live positions are always on the trading page. NFA — not financial advice.

Entry two of the trade journal, and it’s the useful kind: a loss, taken exactly the way the textbooks warn you about, less than 24 hours old as I write this. I got the event right and the trade wrong. Here’s the anatomy.

The trade, in plain numbers

On Thursday evening, July 23, an FDA advisory committee (PCAC — the Pharmacy Compounding Advisory Committee) voted 8–6, one abstention, to recommend that BPC-157, the best-known of seven peptides under review, be added to the list that lets compounding pharmacies legally make it. That’s the exact question Hims & Hers has been positioning around for months — they run their own compounding operation, and they publicly backed the peptides case. The headline I’d been waiting for had arrived.

So I bought it. Three orders that evening: 300 shares after hours around $33.10, then 700 more overnight at $32.99 — 1,000 shares at an average of $33.03, about a $33,000 position.

Friday morning the committee kept voting yes — four of the seven peptides backed so far. The stock opened at $33.81, ticked as high as $34.51… and then fell out of bed. By late morning it was trading around $29.30, down 11% from my cost — roughly $3,700 of paper loss on a morning when every headline was the one the bulls wanted.

29323640Jul 1Jul 6Jul 10Jul 15Jul 20Jul 23YTD high 38.28staff docs → −9%vote day: spike + fadenext morning 29.1my entry 33.03
Meeting week, close up. The rally into the event, the −9% day when FDA staff’s “none of them qualify” position hit the tape, the vote-day spike to 35.85 that faded to a red close — where I bought the evening dip at $33.03 — and the next-morning flush to ~$29. Friday’s candle is intraday, not final.

The three-month runway I watched from the sidelines

Here’s the part that stings: none of this was a surprise. In mid-April, FDA put the peptides question on its public calendar — a named committee, a posted date, a specific list of seven substances. That announcement was the starting gun, and the market heard it. HIMS ran from the mid-$20s in April to a closing high of $38.28 on July 6 — roughly +58% in under three months, most of it on exactly this story.

The pricing-in idea, ELI5: when good news has a date on it, nobody waits for the date. Every trader who believes the news will be good buys ahead of it — that’s what the three-month rally was. By the time the meeting arrived, everyone who wanted in was already in, at an average price way below mine. The vote didn’t create buyers. It released sellers.

FebMarAprMayJunJulApr: FDA sets the datestaff say nopanel votes yes29.5429.5224.97
HIMS in 2026. FDA put the peptides question on the calendar in mid-April and the stock ran roughly +58% into early July — that run was the market pricing in a yes. Gray dashed line: what the average 2026 buyer paid ($24.97). Purple: the average buyer since the May earnings report ($29.52). The dot is my entry — the very end of the story.

The week before the meeting even gave me a dress rehearsal of the risk. FDA’s own staff published their homework ahead of the vote: in their view, none of the seven peptides qualified. The stock logged its worst week in two months, including a −9% day, and kept sliding into the meeting. The setup was public: staff opposed, stock extended, date known.

Why “yes” made the stock go down

Two mechanical reasons, no conspiracy required.

First: the yes was already owned. The people who believed in a yes had three months to buy it, and they did — that was the +58% run. When the vote landed, their trade was complete. A catalyst you can see coming works like a finish line: the crowd doesn’t start running when the tape breaks, they stop. I bought the tape-break.

Second: the yes decided nothing. An advisory committee recommends; FDA decides, months from now, and FDA’s own scientists had just published that they’d say no. So the bull case didn’t get de-risked on Thursday — it got capped: the best available headline had now been spent, and the remaining scheduled event is the harder one. Nobody with new money had a reason to chase, and everybody with old money had their exit liquidity. Which was me. I wasn’t buying a catalyst; I was buying the ribbon-cutting on a building everyone had already toured.

My own tools called it

This is the part I most need to write down. The night I bought, my momentum scanner’s card for HIMS read AVOID. Not because the company is bad — because the funnel is built to refuse exactly this trade. The stock was 27% above the average price every 2026 buyer had paid (stretched), and its momentum had been running behind the S&P for all of July (the fast money’s enthusiasm was already spent). Extended and lagging is the signature of a story that’s been fully bought.

I had rules. The rules worked. I overrode them because the story was exciting and the headline felt imminent. The market pricing it in wasn’t a detail I missed — it was the entire trade, and it was visible in two numbers I look at every day.

The fix: scan for decision points, not decisions

The lesson isn’t “avoid catalysts.” It’s that a scheduled catalyst has two tradeable moments: the day the date is announced (April, stock in the mid-$20s, narrative empty) and the day it resolves (July, stock at $33, narrative full). I showed up only for the second one. The whole edge lived in the gap between them.

So I’ve put an agent on it. My openclaw box now runs a horizon-scanning loop (Grok 4.5 under the hood) that reads FDA advisory calendars, Federal Register notices, agency dockets, and filings looking for one specific shape: a regulatory body just committed to deciding something material, on a date weeks or months out, and specific public companies have leverage to the outcome. Score it by time remaining and how early the narrative is; flag it while it’s still boring. Its job is not to predict votes — it’s to make sure I’m looking at April’s announcements in April, so the position gets built during buy-the-rumor instead of donated during sell-the-news. The daily output publishes as briefs on the trading page.

The plan from here

I’m still holding the 1,000 shares, and the framework I ignored on entry is the one I’ll obey on exit. The stock is currently testing the average price of everyone who bought since the May earnings report (~$29.50) — the first real line of support. Below that, the floor that matters is the year’s average buyer price around $25: if HIMS closes below it, every 2026 cohort is underwater, the chase has become a broken trade, and I’m out — no averaging down into a mistake. Above, this isn’t anything but damage control until it reclaims the pre-flush level near $32.70.

Next dated event is Q2 earnings on August 10. The undated one — FDA’s actual decision on the list — is precisely the kind of far-off catalyst the horizon scanner exists for. I will not be paying full price for the same story twice.

Disclosure (NFA)

Not financial advice. I hold positions in ABT, HIMS, and HOOD (shares and call options), and I may buy or sell any of them without updating this post. This is a personal trading journal — me showing my work, not recommending it. Do your own research.